Imexpharm Corp (IMP) - Total Liabilities
Based on the latest financial reports, Imexpharm Corp (IMP) has total liabilities worth ₫442.31 Billion VND (≈ $16.81 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Imexpharm Corp - Total Liabilities Trend (2019–2025)
This chart illustrates how Imexpharm Corp's total liabilities have evolved over time, based on quarterly financial data. Check Imexpharm Corp liquidity resilience to evaluate the company's liquid asset resilience ratio.
Imexpharm Corp Competitors by Total Liabilities
The table below lists competitors of Imexpharm Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DCX Systems Limited
NSE:DCXINDIA
|
India | Rs6.45 Billion |
|
SILICOM LTD IS-01
F:S1L
|
Germany | €42.78 Million |
|
AME Elite Consortium Bhd
KLSE:5293
|
Malaysia | RM1.09 Billion |
|
HMH Holding Inc. Class A Common Stock
NASDAQ:HMH
|
USA | $683.00 Million |
|
Ascom Holding AG
SW:ASCN
|
Switzerland | CHF119.70 Million |
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
Turkey | TL1.88 Billion |
|
Prosafe SE
OL:PRS
|
Norway | Nkr351.70 Million |
|
Suheung Capsul
KO:008490
|
Korea | ₩520.12 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Imexpharm Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Imexpharm Corp assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imexpharm Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imexpharm Corp (2019–2025)
The table below shows the annual total liabilities of Imexpharm Corp from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₫476.11 Billion ≈ $18.09 Million |
+48.02% |
| 2024-12-31 | ₫321.66 Billion ≈ $12.22 Million |
+4.42% |
| 2023-12-31 | ₫308.04 Billion ≈ $11.70 Million |
-19.47% |
| 2022-12-31 | ₫382.50 Billion ≈ $14.53 Million |
-23.55% |
| 2021-12-31 | ₫500.29 Billion ≈ $19.01 Million |
+36.70% |
| 2020-12-31 | ₫365.97 Billion ≈ $13.90 Million |
+26.95% |
| 2019-12-31 | ₫288.29 Billion ≈ $10.95 Million |
-- |
About Imexpharm Corp
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and mine… Read more